Monthly Archives: January 2020

Supergirl: Every Change After Crisis On Infinite Earths – Screen Rant

Posted: January 27, 2020 at 12:15 am

Warning: SPOILERS for Supergirl, season 5, episode 10, "The Bottle Episode."

Many things changed for Supergirl in the wake of theCrisis on Infinite Earths crossover event. Indeed, so much has changed for Kara Zor-El and her allies it is surprising that the on-going storylines ofseason 5have remained largely intact.

Of all the series making up the Arrowverse, Supergirl had perhaps the most to alter, as every superhero series on The CW was merged into a single universe. With a setting where most of the super-powered beings were aliens rather than metahumans, Supergirl stood apart from The Flash and Black Lightning. This was largely due to Supergirl starting off on another network and not originally having been designed to be part of the Arrowverse.

Related: How Supergirl Will Be A Different Show After Crisis on Infinite Earths

The series adapted admirably as it made the leap to The CW, however, and now stands as a pillar of the largest shared universe in television history. Yet so much has changed in the span of two episodes it would be easy for even die-hard Super-fans to have missed all the little changes between Earth-38 and Earth Prime. Here's a rundown of all the differences.

"Crisis on Infinite Earths - Part 5" left Supergirl reeling, as she woke up on a new Earth where Lex Luthor was a respected philanthropist and hero to most of the world. It got worse when she discovered that Luthor now owned the Department of Extranormal Operations (DEO) and was effectively her boss. A new wrinkle was introduced in "The Bottle Episode," as Supergirl saw a commercial where she was standing proudly alongside Lex Luthor, Lena Luthor, and a team of DEO agents, assuring the public that they could be counted on to protect them. This was quite different from Earth-38, where the DEO was a covert organization that did not officially exist.

Kara ranted about having to work with Luthor to her sympathetic sister, who didn't originally remember Lex Luthor's criminal past. In "Crisis On Infinite Earths - Part 5," only the Paragons (including Supergirl and Martian Manhunter) knew Lex Luthor for who he once was. "The Bottle Episode" informed us that J'onn was able to telepathically restore the pre-Crisis memories of Alex Danvers, Brainiac-5, Dreamer, Kelly Olsen, and every hero who fought the Anti-Monitor. Beyond them, the rest of the citizens of Earth-Prime have no memory of the multiverse or the Crisis.

Lena Luthor had a literal rude awakening in "The Bottle Episode," finding her brother Lex fixing breakfast in her office kitchen. Lex explained that he had been resurrected by The Monitorand made a bargain before he agreed to help him save the multiverse; that whatever happened, Lena would survive the experience with her mind and memories intact. Lex added that reality had been rewritten so that the family business was back to being LuthorCorp rather than LCorp, and they ran it and the DEO together, with the world thinking they were simple billionaire philanthropists. It was, Lex noted, the perfect cover for world domination, including her plans for Project Non Nocere.

Related: Every Arrowverse Crossover Ranked (Including Crisis On Infinite Earths)

Lena immediately began researching the new Earth and the history she would be expected to know. A quick glance at her browser search in one scene revealed that the world thinks Supergirl and Lex Luthor joined forces to fight Agent Liberty during Supergirl's season 4 finale, where Agent Liberty was originally a puppet in Lex's scheme. The search also revealed that Lex and Lena worked together to cure rare diseases and that Lex bought the DEO after the federal organization became strapped for cash. This suggests that virtually everything in the historical record from the first four and one-half seasons of Supergirl may no longer be valid.

One interesting side-effect of the reborn Earth was that several versions of Brainiac-5 from alternate Earths appeared in the DEO, including a female Braniy from a world where she was the DEO's director. While Supergirl was quick to offer the Brainiacs help in getting back to their home worlds, a typically tactless Brainiac-5 let it slip that there were no more alternate Earths and offered to show them the figures which proved the multiverse as they knew it was no more. This suggests that the Earths making up the new Arrowverse are unable to detect one another's presence, as it was confirmed that there are still multiple Earths in the closing montage of "Crisis on Infinite Earths - Part 5."

Before Crisis on Infinite Earths, a secret, alien-run organization called Leviathan almost destroyed Earth-38 with a massive monsoon and the eruption of a super volcano. Despite a lengthy historical record that spoke of the organization in legend, neither Brainiac-5 nor Lex Luthor (who had been told about the group's existence by his sister) could find any evidence of the group's existence on Earth-Prime. Leviathan still exists, however, though it is nowmanaged by the alienGamemnae and is seeking a subtler, technology-based solution to keeping humanity in check. To that end,Gamemnae has encouraged Obsidian North CEO Andrea Rojas in her plans to develop the most realistic virtual reality system ever, through her guise as Rojas' mentor, Professor Gemma Cooper.

The multiple Brainiac-5's discovered that the wormhole which transported them to Earth-Prime was based around Al's Dive Bar; the alien-friendly establishment where most of National City's aliens went to drink in peace. Upon arriving at the bar, Supergirl and The Brainiacs found that Al's had become Als', with two of the burly bartender now serving drinks to a number of aliens who had just barely escaped the destruction of their respective worlds in other universes. This included a trio of Kryptonian witches, who were non-evil doppelgangers of the witches who once sought to terraform Earth into a New Krypton under the control of the World-Killer Reign.

On Earth-38, Lillian Luthororganized the terrorist group CADMUS, having come to share her son's extreme views on the dangers of aliens on Earth. She was sent to prison for her crimes, but still found ways to aid Lex and Lena in their respective endeavors. On Earth-Prime, Lillian is out of prison and is now in charge of The Luthor Foundation, a charity run by the Luthor family. Lillian is also fully aware of how the world used to be, though this was a result of Lex telling her of his activities during Crisis on Infinite Earths.

The action of the later-half of "The Bottle Episode" centered around the race to stop one of the Brainiac-5 duplicates from accidentally destroying Earth-Prime in a misguided bid to save his own Earth. In a nod to the Bottled City of Kandor from the classic Superman comics, it was revealed that this Brainiac-5 had managed to trap his Earth inside a bottle before the Anti-Monitor destroyed it. Before he could open the bottle, which required special tools that didn't exist on Earth or magic to unseal it, the alternate Brainiac-5 was persuaded to wait until the heroes of Earth-Prime made an effort to find somewhere they could safely release the trapped Earth in normal space. Until that time, the bottle would be kept in the Fortress of Solitude for safe keeping.

Facing multiple versions of himself led Braniac-5 to make a decision he'd been delaying since the Supergirl season 4 finale regarding the inhibitor implants in his forehead. The inhibitors repressed Brainiac-5's full intelligence as well as his connection to the Big Brain; the hive-mind made up of all Coluan intellects. While this still left him more intelligent than the vast majority of sentient beings and gave him greater control of his emotions, he felt outclassed by his other selves. In the end, Brainiac-5 was convinced that he would be just as good and his friends would still like him without the implants, leading to a transformation that left Brainaic-5 looking much more like his comic book counterpart.

Some things haven't changed on Earth-Prime and Lex Luthor's ability to arrange a side-hustle is as strong as ever. He finally convinced Lenato enter into an alliance with him, after briefly bonding with a Truth-Seeker (an alien symbiote that makes it impossible for its host to lie) and admitting that he planned to betray her as soon as she became an inconvenience, just like she was planning to subject him to herNon Nocere treatment as soon as she was able. However, Lena's acceptance of Lex's offer came after a talk with Lillian Luthor, with whom Lex had formed another partnership based around manipulating Lena to their mutual benefit. Finally, Braniac-5 approached Lex and told him that they would have to work together in secret to overcome Leviathan and that he was prepared to do anything for the greater good, even work against his friends in the DEO.

Related: Crisis On Infinite Earths May Have Made Super Friends Arrowverse Canon

As Brainiac-5 and Lex Luthor cemented their new partnership, Luthor suggested his first avenue of investigation into Leviathan should be a particular doppelganger who had come through the wormhole into Earth Prime. Luthor had reason to believe that this man, who had just been arrested, had knowledge of the future and might know something about Leviathan that was unknown in the present. He handed Brainiac-5 a mug-shot of the man, who was clearly Brainiac-5's ally Winn Schott.

On Earth-38, reporter William Dey had taken a position working at CatCo Worldwide Media to get close to Andrea Rojas, whom he suspected was involved in the disappearance of his best friend. Dey is just as much of a crusader on Earth-Prime, but now the focus of his private war is the Luthor family, whom he suspects were involved in the mysterious death of the same friend. This has given Supergirl an unexpected ally in her new mission to expose the truth about Lex Luthor to the world.

More: Batwoman Comes Out As A Lesbian After Crisis (& Supergirl Helps Her)

Why Dwayne Johnson Isnt Returning For Fast & Furious 9

Matt Morrison has been writing about comics since before the word"blogging" was coined. He got his start writing for thelegendary DC Comics digital fanzine Fanzing,before receiving his own column, The Mount. Since then he has gone onto write for over a dozen websites, including 411Mania, ComicsNexus and The Cult of Nobody. He holds both an MS in InformationScience from the University of North Texas and a BFA from theUniversity of Texas at Arlington. Known as a font of comic bookhistory trivia, he has delivered lectures on the history of AmericanComic Books, Japanese Manga and Cosplay at over a dozen conventionsand served as an Expert In-Residence for a course on Graphic Novelsfor Librarians at the University of North Texas. In addition to hiswork for Screen Rant, Matt is currently the Managing Editor ofKabooooom.com, the housecritic of ExploreThe Multiverse and writes reviews for NoFlying, No Tights a graphic literature and anime review siteaimed at teachers and librarians. He also maintains a personal blog My Geeky Geeky Ways which hosts his extensive episode guide for the television seriesmaking up The Arrowverse as well as hiscomedic Lets Play videos. What little spare time he has isdevoted towards acting, role-playing, movie-riffing and sarcasm. Youcan follow his adventures on Twitter, @GeekyGeekyWays.

Read the original:

Supergirl: Every Change After Crisis On Infinite Earths - Screen Rant

Comments Off on Supergirl: Every Change After Crisis On Infinite Earths – Screen Rant

Doctor Strange In The Multiverse Of Madness: The Brand New Character To Debut In The Movie! Air Date And Cast – The Global Coverage

Posted: at 12:14 am

- Advertisement -

If you are a big fan of Doctor Strange and his mind-bending movie, then heres a piece of good news for you. Marvel is back with the second part of Doctor Strange.

So say hello to Doctor Strange in the multiverse of madness. The movie has been confirmed as part of Phase 4 at Comic-Con with a little experimental title.

Also, there is news that filmmaker Scott Derrickson would not be directing the second part of the movie. The announcement was made by himself on the 9th of January. So it will be interesting to know what does this means to the film and what changes will be made?

Source: Comic Book

So far, one Benedict is confirmed for the sequel, Cumberbatch, obviously, but it would be surprising if Benedict Wong wouldnt be back, especially as hes been talking about filming.

In the most intriguing announcement at Comic-Con, Elizabeth Olsen will be joining the team and will be starring as Scarlet Witch. This characters supernatural skillset makes her unbeatable and a perfect match for Stranges world.

As she was seen in one on one fight with Thanos in Avengers: Endgame, it is pretty clear she is one powerful force to be reckoned with.

We can also expect Chiwetel Ejiofor, Mordo, to turn up as a part of the movie.

Rachel McAdams will be back in the movie, presumably, as Christine Palmer, as Strangers sort of love interest.

Source: Animated Times

As far as the release date is considered, May 7, 2021, is the chosen date for its release, making it the fourth movie of Phase 4.

With Derricksons departure as the director, one can assume to wait for a little longer. But, he is still the executive producer. He mentioned on twitter that he is thankful for the collaboration with Marvel and will remain on as EP.

With a new director, all we can do is wait for Marvel to release the movie on the selected date.

- Advertisement -

Go here to read the rest:

Doctor Strange In The Multiverse Of Madness: The Brand New Character To Debut In The Movie! Air Date And Cast - The Global Coverage

Comments Off on Doctor Strange In The Multiverse Of Madness: The Brand New Character To Debut In The Movie! Air Date And Cast – The Global Coverage

Dragon Ball: Every Version of Trunks, Ranked | CBR – CBR – Comic Book Resources

Posted: at 12:14 am

Trunks is one of the most memorable characters in theDragon Ball franchise, largely because there are just so many versions of the character. A time-displaced version of Trunks quickly became a fan-favorite when he was introduced during the "Android Saga" ofDragon Ball Z.

However, thanks to his time travel (along with alternate and sometimes even aborted futures in the form ofDragon Ball GT), there have been multiple versions of Trunks introduced over the years. But how do they stack up against one another? Here's every version of Trunks from across the Dragon Ball multiverse, and how they compare to each other.

RELATED:Dragon Ball: Why Isn't Gohan the Protagonist Anymore?

More of an oddity than an actual character, EX Trunks is a notable fusion from the video game Dragon Ball Fusions. He's a combination of the Future Trunks and the core timeline Kid Trunks. Although they have vastly differentpersonalities as a result of their altered upbringings, their affinity for one another allows their fusion to stand out as one of the most synchronic fusions in the multiverse.

This fusion looks mostly like Future Trunks, although he gains some of the purple hair that Kid Trunks has. They are one of the only two fusions of the same person from two different timelines, the other being the Fused Zamasu (who is a fusion of Future Zamasu and Goku Black). However, there hasn't been much in terms of character shown in the fusion, meaning he's just an interesting look more than anything.

RELATED: Dragon Ball: How Many Planet-Busters Are There?

Dragon Ball GT isn't fondly remembered by much of theDragon Ball fandom. The series (which suffered from sloppy animation and almost nonsensical plot beats) spent a certain amount of time early on focusing on Trunks.GT Trunks has actually become more like his mother than other versions. He briefly runs Capsule Corporation before heading off into space alongside Goku and Pan in search of the Black Star Dragon Balls. It's interesting to see Trunks pick up the more adventurous spirit of his mother and not just his father's Saiyan habits, but he never gets the level of depth or attention that the concept deserves.

Instead, the character (and the show as a whole) are plagued by a poor attempt to fuse the tones of Dragon Ball andDragon Ball Z. After the initial arc in space, Trunks becomes more commonly just one of the Z-Warriors who throws himself into battle. He helps fight against Super 17 and Omega Shenron, more as cannon fodder and a distraction than the main fighter. But he is able to survive these battles and do his part. GT Trunks is one of the better parts ofDragon Ball GT, but he's still a tonally weird version of the character.

RELATED: Dragon Ball Z: Kakarot Reveals What Chi-Chi Does When Goku's Away

Kid Trunks is the version of the character from the core Dragon Ball universe. Born during the time-skip between Frieza's defeat and the arrival of the Androids, Kid Trunks was given the chance to live in a world where the heroes were prepared for the dangers coming for them. Unlike the version who had to live in a battle-ravaged world, Kid Trunks instead got to grow up with his father alive, a best friend in Goten, and eventually even a sister named Bulla.

This version of Trunks has also developed an attitude that other versions lack, having inherited some of his father's prideful boisterous elements. He's also proven incredibly powerful for his age, having the ability to go Super Saiyan on his own and even being capable of hitting Super Saiyan 3 when fused with Gotenks. The problem is that the character didn't get much development duringDragon Ball Z and much of the early parts ofDragon Ball Super. However, his time with Future Trunks during the "Future Trunks" Saga gave the character a surprising amount of depth and self-reflection, making Kid Trunks more engaging as a result.

RELATED: Every Dragon Ball Hunt, Ranked

Xeno Trunks refers to a version of Trunks from theDragon Ball Xenoversecorner of the franchise. At first glance, he's very similar to Future Trunks, with his timeline initially playing out in a very similar way.After defeating the Androids and Cell of his world though, he was whisked away to the mysterious Time Nest. His use of a time machine is considered a crime by the Chronoa, the Supreme Kai of Time. She recruits him as a member of her Time Patrol to make up for his mistakes. Xeno Trunks is tasked with helping protect the timeline from the dangerous Towa and Mira, This Trunks proved to be perhaps the most powerful version of the character in the franchise, as his battles across the timeline have forced him to take on new forms and power levels that haven't been reached by any other version of the character.

This is also a Trunks who made use of two unique fusions: he used the Potara Earrings to fuse with Xeno Vegeta and create Vegeks, and would later use the Fusion Dance with Gohan to create Gohanks. He would eventually even reach levels of power that the core Future Tunks never has, achieving Super Saiyan 3 and even eventually the Super Saiyan God form. This Trunks is a great representation of the battle-heavy side ofDragon Ball, finding new extreme levels of power without adding much in terms of character. He's an impressive warrior but doesn't have that extra level of character depth to make him the best of the bunch.

RELATED: Dragon Ball: Every Pride Trooper, Ranked According To Strength

Future Trunks is the most memorable version of the character, and arguably among the fanbases favorites. His introduction included cutting Frieza in half with a sword, which is a pretty great introduction for any character. It's revealed that this Trunks comes from a timeline where Goku passed away from heart disease. He wasn't there to help fight the Red Ribbon Army Androids, who wiped out the rest of the Z-Warriors -- including Trunks' father Vegeta before he ever got to know him and Piccolo, meaning the Dragon Balls were once more lost. He trained under Gohan (until he died as well) before heading into the past using a time machine constructed by his mother. Future Trunks received a decent amount of attention in his first series of appearances, fighting alongside the Z-Warriors before eventually returning to his own time and completing his own arc.

His eventual return duringDragon Ball Super added even more pathos to the character, giving him a love interest in Mai and a new mortal enemy in Goku Black. The "Future Trunks" arc helps elevate Future Trunks beyond his (already pretty solid) character development fromDragon Ball Zand helps shoot him beyond almost the rest of the entire supporting cast in terms of emotional richness. This is a character who actually recognizes and deals with the trauma of living in a world where laser blasts wipe out entire cities, and it's an engaging take on the universe. There's a melancholy to Future Trunks and his plight that makes him unique to the franchise, and easily one of the engaging characters in the entire world.

Also, he learns how to activate a unique form of power called Super Saiyan Rage, and even figures out how to essentially turn his sword into a spirit bomb-powered lightsaber with a move called the Sword of Hope, and that's just awesome.

KEEP READING: Dragon Ball Z: A History Of (Mostly Bad) Video Games

Marvel's Blackest Night Just DESTROYED the DC Universe

Tags:dragon ball,feature

Read more from the original source:

Dragon Ball: Every Version of Trunks, Ranked | CBR - CBR - Comic Book Resources

Comments Off on Dragon Ball: Every Version of Trunks, Ranked | CBR – CBR – Comic Book Resources

City Theatrical Now Shipping QolorFLEX 5×2.5A Multiverse Dimmers – EtNow.com

Posted: at 12:14 am

City Theatricals QolorFLEX 5x2.5A Multiverse dimmers, which are constant voltage, five-output, miniature dimmers that can be controlled wirelessly, are now available through City Theatrical distributors worldwide. Recently recognised with an honourable mention in the Lighting Control category at the LDI Show 2019 Best Debuting Product Awards, QolorFLEX 5x2.5A Multiverse Dimmers have built a foundation for City Theatricals family of miniature low voltage wireless dimmers with Multiverse* wireless DMX/RDM connectivity.

Available in dual band 900MHz/2.4GHz (P/N 5942)** or 2.4GHz band only (P/N 5943), QolorFLEX 5x2.5A Multiverse dimmers be controlled wirelessly using City Theatricals Multiverse wireless DMX/RDM or SHoW DMX Neo wireless DMX/RDM technology, or with wired DMX. These dimmers provide 20-bit PWM resolution and 8-bit or 16-bit control for extremely smooth dimming at the low end of the dimming curve.

QolorFLEX 5x2.5A Multiverse dimmers use detachable input and output connectors to make wiring easy. Configuration is performed using RDM, such as with a City Theatrical DMXcat multi-function test tool, or with City Theatricals USB Configuration program for PC/Mac. A mounting bracket is included with the Dimmer to allow easy mounting to scenery.

QolorFLEX 5x2.5A Multiverse dimmers are designed and built in the USA by City Theatrical. They pair perfectly with QolorFLEX five-in-one LED Tape for ideal use in props and costumes, or for areas where space is a concern.

For more information on QolorFLEX 5x2.5A Multiverse Dimmers, visit: http://www.citytheatrical.com/Products/qolorflex-5x2-5a-multiverse-dimmer

*Multiverse Transceivers are covered by U.S. Patent # 7,432,803 and other patents pending.

**900MHz band is licensed for use in North America only.

QolorFLEX 5x2.5A 900MHz/2.4GHz Multiverse dimmer (P/N 5942) is a constant voltage, five-output dimmer that can be controlled wirelessly using City Theatricals Multiverse or SHoW DMX Neo wireless DMX/RDM technology, or with wired DMX.

View original post here:

City Theatrical Now Shipping QolorFLEX 5x2.5A Multiverse Dimmers - EtNow.com

Comments Off on City Theatrical Now Shipping QolorFLEX 5×2.5A Multiverse Dimmers – EtNow.com

More railroad and highway closures in Ascension Parish Friday – WBRZ

Posted: at 12:14 am

PRAIRIEVILLE - The railroad crossing at La. 73 near Airline Highway will likely be closed until Thursday afternoon and drivers should expect evening and morning delays in Ascension Parish.

The railroad company is doing work on its tracks and requires the highway be closed. DOTD has been alerting drivers of the ongoing progress.

Originally scheduled to be open by 5 p.m. Wednesday, a mechanical issue at the worksite delayed the crossing being open until Thursday at 2 p.m.

DOTD posted this warning:

The Louisiana Department of Transportation and Development advises motorists that on Wednesday, January 22, 2020 starting at 7:00 a.m., LA 73 (Old Jefferson Highway) near its intersection with US 61 (Airline Highway.) in Ascension Parish will be closed. This road closure is scheduled to take place until 5:00 p.m.onThursday, January 23, 2020and is necessary to allow KCS Railroad to perform maintenance on its tracks.

Plan for delays. Click HERE for a live traffic map from WBRZ.

The railroad closure caused chaotic traffic congestion in parts of Ascension Wednesday morning.

Other Wednesday closures included Highway 74, New River Street and Ascension Street.

Additionally, the city of Baton Rouge announced two different spots on College Drive and Pecue Lane will be closed for roadwork from 7 a.m. to 7 p.m. Saturday.

A full list of closures to expect from Jan. 20 to Jan. 25 are listed below:

-January 21- Post Office Road and Duplessis Road

-January 22- Highway 73, Highway 74, New River Street, and Ascension Street

-January 23- Coolidge Ave., Felix Ave., and Purpera Road

-January 24- Highway 30, Railroad Street (Sorrento)

-January 25- Highway 621, College Drive @ Perkins, Pecue Lane @ Perkins

Most of these closures are expected to last from 7 a.m. until 5 p.m., each day and are necessary to allow KCS Railroad to perform maintenance on its tracks.

Closures of crossings in East Baton Rouge are expected in the future but those have not been scheduled, a railway spokesperson told WBRZ.

Continued here:

More railroad and highway closures in Ascension Parish Friday - WBRZ

Posted in Ascension | Comments Off on More railroad and highway closures in Ascension Parish Friday – WBRZ

Professionals share a roundup of what they expect to be 2020’s top health trends – The Oakland Press

Posted: at 12:14 am

Trends come and trends go and the medical field is no exception. As we start a new year, many health providers expect technology will play a larger role in healthcare throughout 2020 and the next decade.

A big reason for this is the amount of technology-driven tools that put patient care in their own hands. Devices like Fitbit, Apple Watch and Garmin watches can help with numerous health tasks from tracking your blood pressure and monitoring your heart rate to measuring your sleep quality and counting the number of calories in your meals.

Jason Whateley, D.O., physician, Ascension Medical Group has noticed how more patients are wearing technology gadgets as they engage in healthy activities. This allows them to see their progress and track results, making it easier for them to stay focused on achieving their goals, he said.

Wearable technology was number one under the American College of Sports Medicine Worldwide survey of fitness trends for 2020, he said in an email. The convenience and ease of these devices is what attracts patients.

However, while these devices have made great strides in patients health, Whateley explained that they still have their limitations.

Patients need to realize results they are obtaining from these devices are much more limited compared to what a complete diagnostic test can provide. Working with a health care provider fills in the gaps that these home gadgets and applications are lacking, he said.

Beyond exercise-specific technology, people need to be aware of the role technology plays in their everyday lives, said Dr. Kurtis Kieleszewski, family medicine physicians, McLaren Macomb.

Technology in general has a detrimental impact on many of American's health because by being plugged in and staring at a screen, we're likely less active and engaging with one another less and less, he said.

Technology can also change the way patients interact with medical providers. Ascension Online Care is designed for patients in need of after-hours care. This service is much like a virtual urgent care clinic where patients receive one-on-one care using their smartphone, tablet or laptop to video chat with a physician who reviews their symptoms and provides the care they need in real time. A summary of their visit is also sent to their Ascension primary care doctor.

So as they track their progress, what activities are people choosing to participate in? There is definitely a trend toward High intensity interval training (HIIT), which is now listed second under the American College of Sports Medicine Worldwide survey of fitness trends for 2020, said Whateley.

These programs focus on short bursts of high-intensity exercise followed by a short rest period. The big appeal of these exercises is that they can be done at home with little or no equipment, he said.

Kieleszewski said he encourages his patients to move most days of the week.

However they can fit that in their busy schedules and whichever method(s) fit their budget, he said in an email. A blend of cardiovascular and resistance training is usually ideal for everyone to optimize their physical and mental health.

Despite the popularity of home gyms, dont expect joining a gym to fall out of favor. Whateley said those looking for access to more equipment, group sessions and strength training will continue their gym memberships.

For years, those struggling with mental health issues have faced an unwelcome stigma and an uphill road. New trends show that attitudes toward mental health continue to evolve, making it easier for people to seek out care if they need it.

Hopefully all matters relating to mental health will be valued and emphasized as they rightfully should be, said Kieleszewski.

He said the delay in patients seeking assistance and the sometimes limited resources for mental health patients to be evaluated and treated by specialists are challenges for many.

Mental health affects every facet of our daily lives and we as a society need to be more compassionate to those it affects, said Whateley. I believe this trend will continue to be a major focus in 2020 along with aiding those with addiction.

Failing to get a good nights rest may be depriving you of more than you think.

Not getting enough sleep has been attributed not only to our mood and focus but also to many chronic conditions such as diabetes, stroke and cardiovascular disease, said Whateley. As physicians we place a lot of focus on preventive medicine. Improving your sleep quality can aid in avoiding these diseases.

He shared these strategies from the Centers of Disease Control and Prevention that can help you improve the quality of your sleep starting tonight:

Be consistent. Go to bed at the same time each night and get up at the same time each morning, including on weekends

Make sure your bedroom is quiet, dark, relaxing and at a comfortable temperature

Remove electronic devices, such as TVs, computers and smartphones, from the bedroom

Avoid large meals, caffeine and alcohol before bedtime

Get some exercise. Being physically active during the day can help you fall asleep more easily at night

Consult your health care provider to rule out other underlying diseases that may be affecting your sleep

View original post here:

Professionals share a roundup of what they expect to be 2020's top health trends - The Oakland Press

Posted in Ascension | Comments Off on Professionals share a roundup of what they expect to be 2020’s top health trends – The Oakland Press

Google CEO eyes major opportunity in healthcare, says will protect privacy – Reuters

Posted: at 12:14 am

Sundar Pichai, Chief Executive Officer of Alphabet, gestures as he speaks during a session of the 50th World Economic Forum (WEF) annual meeting in Davos, Switzerland, January 22, 2020. REUTERS/Denis Balibouse

DAVOS, Switzerland (Reuters) - Sundar Pichai, the CEO of Alphabet Inc and its Google subsidiary, said on Wednesday that healthcare offers the biggest potential over the next five to 10 years for using artificial intelligence to improve outcomes, and vowed that the technology giant will heed privacy concerns.

U.S. lawmakers have raised questions about Googles access to the health records of tens of millions of Americans. Ascension, which operates 150 hospitals and more than 50 senior living facilities across the United States, is one of Googles biggest cloud computing customers in healthcare.

When we work with hospitals, the data belongs to the hospitals, Pichai told a conference panel at the World Economic Forum in Davos, Switzerland.

But look at the potential here. Cancer if often missed and the difference in outcome is profound. In lung cancer, for example, five experts agree this way and five agree the other way. We know we can use artificial intelligence to make it better, Pichai added.

Google has spent several years developing artificial intelligence to automatically analyze MRI scans and other patient data to identify diseases and make predictions aimed at improving outcomes and reducing cost.

The U.S. lawmakers asked the company in November to provide information about other health systems that provide information to Google, whether Ascension clients will be allowed to opt out of the project, and whether the data be used for advertising.

Pichai said there was already strong privacy protecting regulations in place that provide a framework for Google to operate.

Google clinched a deal in November to acquire Fitbit Inc for $2.1 billion, aiming to enter the wearables segment and invest in digital health. The acquisition is expected to be scrutinized closely by regulators before it is allowed to close.

(This story corrects reference to Ascension from biggest to one of the biggest cloud computing customers in healthcare in 2nd paragraph)

Reporting by Greg Roumeliotis in Davos, Switzerland; Editing by Alex Richardson

Link:

Google CEO eyes major opportunity in healthcare, says will protect privacy - Reuters

Posted in Ascension | Comments Off on Google CEO eyes major opportunity in healthcare, says will protect privacy – Reuters

Proteostasis Therapeutics Announces Keystone Symposia Presentation of Organoid Study from More than 300 Adult CF Patients – Yahoo Finance

Posted: at 12:13 am

Ex vivo Data with Proteostasis' CFTR Modulators in non-F508del and non-G551D CF Genotypes Marks First Step Toward a Personalized Medicine Approach

BOSTON, Jan. 22, 2020 /PRNewswire/ --Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, today announced the presentation of results from an ex vivo study of the Company's proprietary cystic fibrosis transmembrane conductance regulator (CFTR) modulators in organoids from individuals with CF who are ineligible for the current standard of care CFTR modulator therapies due to their genotype, a population of approximately 2,300 adults in Europe alone. The results, outlined in a poster entitled "Intestinal Organoid Models as a Path for Personalized Therapy Development in Cystic Fibrosis," will be presented at the Keystone Symposia on Tissue Organoids taking place on January 19-23, 2020 in Vancouver, BC, Canada.

The study remains on track for collecting tissue samples from up to 500 CF patients with less common genotypes by the end of Q1 2020 for assaying as organoids and for testing responsiveness to investigational CFTR modulators, including Proteostasis' CFTR potentiator, corrector and amplifier, dirocaftor (DIR), posenacaftor (POS) and nesolicaftor (NES), respectively. Data from the organoid study will be used to select a subset of patients for a confirmatory clinical trial, known as the CHOICES trial (Crossover trial based on Human Organoid Individual response in CF - Efficacy Study). This organoid program is a strategic initiative funded by the European Commission, which has invited a select number of drug developers and leading researchers in CF to build a roadmap for personalized therapeutics in CF. Based on the outcome of the study, this transition from precision to personalized medicine for the treatment of CF could begin in patients with less common mutations.

The organoid study seeks to measure the ex vivo responsiveness to the PTI CFTR modulators in tissue samples collected via a rectal suction procedure. The rectal tissue is developed into an organoid or a miniaturized organ that is genetically identical to the patient donor and shares the same micro-anatomy as the organ from which they were derived. Organoid cultures frommore than370 adult CF patients have been established to date. Based on initial genotype analysis, approximately 85% of enrolled patients carry genotypes that lead to CFTR protein synthesis making them eligible for ex vivo study with DIR, POS and NES. Data from the organoid study will be used to select a subset of patients for the confirmatory CHOICES clinical trial. The poster outlining these results is available on the Company's website at proteostasis.com.

"With advancements in models such asorganoid testing used to predict the effectiveness of CFTR modulator treatments, the transition from precision to personalized medicine in this disease is an inevitability," saidGeoffrey Gilmartin, M.D., M.M.Sc., Chief Medical Officer ofProteostasis Therapeutics. "Essential to this transition is the introduction of more therapeutic options that expand the treatment choices for patients and physicians. As the only company in the HIT-CF consortium with a proprietary combination of novel CFTR modulators that have demonstrated positive Phase 2 data, we remain very enthusiastic about its progress and the translation of these results to the clinic in the CHOICES trial."

"Access to CFTR modulators in Europe is challenged by either the ineligibility of patients for approved drugs due to their genotype, or by the lack of reimbursement for approved drugs due to their high cost," saidCornelis K. van der Ent, Professor at the Department of Pediatric Pulmonology of the Wilhelmina Children's Hospital at the University Medical Center in Utrecht, the Netherlands and HIT CF Project Coordinator. "An organoid-assay-based personalized medicine approach offers the potential of a new decision-supporting technology to inform clinical decisionsand provide each patient with CFTR modulators that lead to their highest possible benefit."

Story continues

CHOICES, which is expected to initiate in mid-2020, will be the first ever personalized medicine-based study in CF. Fully funded by the HIT-CF, this trial is a placebo controlled, double blind, crossover study with an 8-week treatment period and 6 months of uninterrupted dosing. The CHOICES trial will complement the MORE trial (Modulator Options to RestorE CFTR study), a global, Phase 3, randomized, placebo-controlled study in CF subjects with the common F508del homozygous mutation, which is designed to confirm the positive efficacy and tolerability results from a recently completed Phase 2 study of the Proteostasis CFTR modulator triple combination.

About HIT-CF Europe

HIT-CF Europe is a research project which aims to provide better treatment and better lives for people with cystic fibrosis (CF) and rare mutations. To achieve this, drug candidates are first tested on patient-derived organoids in qualified laboratories across Europe. Subsequently, based on the measured signal in the organoids, a smaller group of patients will be invited to participate in a clinical trial. All participating centers are part of the European Cystic Fibrosis Society Clinical Trial Network (ECFS-CTN). The project has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement number 755021. For more information, visit http://www.hitcf.org.

About Proteostasis Therapeutics, Inc.

Proteostasis Therapeutics, Inc. is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis and other diseases caused by dysfunctional protein processing. Headquartered in Boston, MA, the Proteostasis Therapeutics team focuses on identifying therapies that restore protein function. For more information, visit http://www.proteostasis.com.

Safe Harbor

To the extent that statements in this release are not historical facts, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "aim," "may," "will," "expect," "anticipate," "estimate," "intend," and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Examples of forward-looking statements made in this release include, without limitation, statements regarding the potential of our proprietary combination therapies for the treatment of CF, the potential benefit to patients of our proprietary combination therapies, expected timing of patient enrollment in our clinical studies and cohorts for our clinical programs, including our planned Phase 3 programs and initiation of registrational or pivotal studies. Forward-looking statements made in this release involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements, and we, therefore cannot assure you that our plans, intentions, expectations or strategies will be attained or achieved. Such risks and uncertainties include, without limitation, the possibility final or future results from our drug candidate trials (including, without limitation, longer duration studies) do not achieve positive results or are materially and negatively different from or not indicative of the preliminary results reported by the Company (noting that these results are based on a small number of patients and small data set), uncertainties inherent in the execution and completion of clinical trials (including, without limitation, the possibility that FDA or other regulatory agency comments delay, change or do not permit trial commencement, or intended label, or the FDA or other regulatory agency requires us to run cohorts sequentially or conduct additional cohorts or pre-clinical or clinical studies), in the enrollment of CF patients in our clinical trials in a competitive clinical environment, in the timing of availability of trial data, in the results of the clinical trials, in possible adverse events from our trials, in the actions of regulatory agencies, in the endorsement, if any, by therapeutic development arms of CF patient advocacy groups (and the maintenance thereof), and those set forth in our Annual Report on Form 10-K for the year ended December 31, 2018, our Quarterly Report on Form 10-Q for the quarter ended September 30, 2019 and our other SEC filings. We assume no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACTS:

Investors:David Pitts / Claudia StyslingerArgot Partners212.600.1902david@argotpartners.com/ claudia@argotpartners.com

Media:David RosenArgot Partners212.600.1902david.rosen@argotpartners.com

View original content:http://www.prnewswire.com/news-releases/proteostasis-therapeutics-announces-keystone-symposia-presentation-of-organoid-study-from-more-than-300-adult-cf-patients-300990860.html

SOURCE Proteostasis Therapeutics, Inc.

Read the rest here:

Proteostasis Therapeutics Announces Keystone Symposia Presentation of Organoid Study from More than 300 Adult CF Patients - Yahoo Finance

Posted in Cf | Comments Off on Proteostasis Therapeutics Announces Keystone Symposia Presentation of Organoid Study from More than 300 Adult CF Patients – Yahoo Finance

Point Leamington mother hopes Canada will green light latest cystic fibrosis treatment – The Telegram

Posted: at 12:13 am

NICHOLAS MERCER

THE CENTRAL VOICE

POINT LEAMINGTON, N.L. Kelly Earle is an expert in navigating the halls of the Janeway Childrens Hospital in St. Johns.

For the last year, Earle and her 13-year-old daughter Sammi-Jo James have visited the Janeway once a month for checkups. Those visits can turn into 14-day stays as James is treated for cystic fibrosis, a disease which attacks her lungs and digestive system.

The Point Leamington resident has no problem showing someone how to get to the cafeteria or find a certain hospital wing. When she escorts people around, she will tell herself she is a tour guide.

Earles probably seen too much of the Janeways hallways and waiting rooms.

While those trips to the Janeway are sure to continue well into 2020, Earle has some renewed hope that a new treatment for her daughter could be on the horizon.

A new drug named Trikafta was approved in the United States in October and it offers a game-changing treatment for those with cystic fibrosis. It has not been approved by Health Canada.

Under the Food and Drug Administration, Trikafta was approved for use by cystic fibrosis patients 12-years-old or older and who have the most common form of the disease.

James fits both of the criteria.

(Trikafta) is the only hope for Sammi other than therapy and a lung transplant, said Earle.

Earle joins a long list of Canadian patients who are calling for all levels of the Canadian government to bring this drug to the country.

An online petition started by Cystic Fibrosis Canada currently has over 31,000 pledges for action.

Earle has spoken to Coast of Bays-Central-Notre Dame MP Scott Simms, her federal representative, about helping to push the approval of the drug through Health Canada.

Sometimes Ill look at stuff about Trikafta on the computer and Ill have to walk away, said Earle. Ill think (Sammis health) could be changed in a couple of weeks.

Her daughter often stays in the same fourth floor room for her two week stays. They call it James bedroom.

Earle doesnt know the exact room number, but the way to it is singed into her memory.

She gets there by instinct and muscle memory.

If (James) gets admitted it is a relief, said Earle who always packs for a 14-day stay ahead of their monthly Janeway trip. I know she is going to get better.

Crashing down

James was diagnosed with cystic fibrosis at 33 months old. Until then, she always had health problems and couldnt keep food down.

The news sent shockwaves through Earles world.

My world crashed then, she said. Any normal that I knew before that was shattered.

Her life became filled with hospital trips as the Janeway, and Ronald McDonald House became a second home. It also filled with treatments at home and school.

James often experiences bouts of coughing that lead to nausea. She might lose a couple of pounds when this happens.

In November, she had a feeding tube placed in her stomach to deliver nutrients she needs. Along with medication, she uses this tube to feed for 10 hours at night.

CF is progressive, said Earle. The healthiest she is, is right now.

At the end of each day, Im thankful that we got through that day. Only thing I can say is that this is a good day.

Sometimes, James sheds tears as she goes through a procedure during those long hospital stays. They never last long and shell apologize shortly after.

She is a strong person and her mother marvels at her strength.

The things that Sammi have had to go through, me personally, I wouldnt be able to do them, said Earle.

Earle will catch herself watching her daughter as she scrolls through YouTube and becomes engrossed in her favourite videos.

Her mother will experience an explosion of memories. Shell see James cutting a cake as the 2019 Janeway Childrens Miracle Network champion and the subsequent trip to Florida they took because of it.

In her minds eye, Earle sees a smart and bubbly girl who meets every day with a smile.

You make it fun. You take lots of pictures, you make lots of memories and you have lots of fun, she said.

nicholas.mercer@thecentralvoice.ca

Originally posted here:

Point Leamington mother hopes Canada will green light latest cystic fibrosis treatment - The Telegram

Posted in Cf | Comments Off on Point Leamington mother hopes Canada will green light latest cystic fibrosis treatment – The Telegram

CF Industries (NYSE:CF) Rating Increased to Buy at ValuEngine – Slater Sentinel

Posted: at 12:13 am

ValuEngine upgraded shares of CF Industries (NYSE:CF) from a hold rating to a buy rating in a research note issued to investors on Wednesday, January 8th, ValuEngine reports.

A number of other research firms have also recently issued reports on CF. Cowen upped their price target on shares of CF Industries from $59.00 to $62.00 and gave the company an outperform rating in a report on Thursday, September 26th. Zacks Investment Research cut shares of CF Industries from a buy rating to a hold rating and set a $49.00 target price for the company. in a research note on Monday, November 4th. Consumer Edge started coverage on shares of CF Industries in a research note on Monday, September 23rd. They issued an overweight rating for the company. Scotiabank cut shares of CF Industries from an outperform rating to a sector perform rating and set a $48.00 target price for the company. in a research note on Wednesday, September 18th. Finally, Bank of America raised shares of CF Industries from a neutral rating to a buy rating and set a $56.00 price target for the company in a research report on Monday, November 25th. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating and six have assigned a buy rating to the companys stock. The stock currently has an average rating of Hold and a consensus target price of $50.80.

Shares of NYSE CF traded down $1.57 during mid-day trading on Wednesday, reaching $40.93. The company had a trading volume of 2,503,762 shares, compared to its average volume of 2,277,601. The stock has a market capitalization of $9.29 billion, a PE ratio of 18.78, a price-to-earnings-growth ratio of 2.91 and a beta of 0.95. CF Industries has a twelve month low of $38.90 and a twelve month high of $55.15. The stocks 50 day moving average is $45.99 and its 200-day moving average is $47.41. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.10 and a current ratio of 1.34.

In related news, Director Stephen A. Furbacher sold 3,500 shares of the firms stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $47.50, for a total transaction of $166,250.00. Following the sale, the director now directly owns 49,187 shares in the company, valued at $2,336,382.50. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Bert A. Frost sold 13,000 shares of CF Industries stock in a transaction on Thursday, November 21st. The shares were sold at an average price of $45.50, for a total transaction of $591,500.00. Following the completion of the sale, the vice president now owns 95,072 shares in the company, valued at $4,325,776. The disclosure for this sale can be found here. 2.00% of the stock is currently owned by company insiders.

Several institutional investors have recently added to or reduced their stakes in the company. North Star Investment Management Corp. bought a new stake in shares of CF Industries during the 3rd quarter worth about $30,000. Huntington National Bank bought a new stake in shares of CF Industries during the 4th quarter worth about $31,000. Parallel Advisors LLC boosted its holdings in shares of CF Industries by 103.7% during the 3rd quarter. Parallel Advisors LLC now owns 725 shares of the basic materials companys stock worth $36,000 after buying an additional 369 shares during the period. CSat Investment Advisory L.P. boosted its holdings in CF Industries by 27.5% in the 2nd quarter. CSat Investment Advisory L.P. now owns 1,010 shares of the basic materials companys stock valued at $47,000 after purchasing an additional 218 shares during the period. Finally, B & T Capital Management DBA Alpha Capital Management bought a new stake in CF Industries in the 3rd quarter valued at about $60,000. Institutional investors own 93.48% of the companys stock.

About CF Industries

CF Industries Holdings, Inc manufactures and distributes nitrogen fertilizers and other nitrogen products worldwide. Its principal nitrogen fertilizer products include ammonia, granular urea, urea ammonium nitrate solution, and ammonium nitrate. The company also offers diesel exhaust fluid, urea liquor, nitric acid, and aqua ammonia products, as well as compound fertilizer products with nitrogen, phosphorus, and potassium.

Read More: Different Types of Derivatives

To view ValuEngines full report, visit ValuEngines official website.

Receive News & Ratings for CF Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CF Industries and related companies with MarketBeat.com's FREE daily email newsletter.

Read the original:

CF Industries (NYSE:CF) Rating Increased to Buy at ValuEngine - Slater Sentinel

Posted in Cf | Comments Off on CF Industries (NYSE:CF) Rating Increased to Buy at ValuEngine – Slater Sentinel